Exclusive: Journal bans drug safety database papers as they flood the literature
Starting around 2023, a curious trend took hold in papers on drug safety monitoring. The number of articles published on an individual drug and its link to specific adverse events went from a steady increase to a huge spike. The data source in most of those articles was largely the same: The FDA Adverse Events … Continue reading Exclusive: Journal bans drug safety database papers as they flood the literature